by Soung-Hoon Lee, Juyong Yoon, Seung Ho Shin, Muhamad Zahoor, Hyoung Jun Kim, Phil June Park, Won-Seok Park, Do Sik Min, Hyun-Yi Kim, Kang-Yell Choi
Background Alopecia is the common hair loss problem that can affect many people. However, current therapies for treatment of alopecia are limited by low efficacy and potentially undesirable side effects. We have identified a new function for valproic acid (VPA), a GSK3ß inhibitor that activates the Wnt/ß-catenin pathway, to promote hair re-growth in vitro and in vivo.
Methodology/ Principal Findings Topical application of VPA to male C3H mice critically stimulated hair re-growth and induced terminally differentiated epidermal markers such as filaggrin and loricrin, and the dermal papilla marker alkaline phosphatase (ALP). VPA induced ALP in human dermal papilla cells by up-regulating the Wnt/ß-catenin pathway, whereas minoxidil (MNX), a drug commonly used to treat alopecia, did not significantly affect the Wnt/ß-catenin pathway. VPA analogs and other GSK3ß inhibitors that activate the Wnt/ß-catenin pathway such as 4-phenyl butyric acid, LiCl, and BeCl2 also exhibited hair growth-promoting activities in vivo. Importantly, VPA, but not MNX, successfully stimulate hair growth in the wounds of C3H mice.
Conclusions/ Significance Our findings indicate that small molecules that activate the Wnt/ß-catenin pathway, such as VPA, can potentially be developed as drugs to stimulate hair re-growth.
